Albireo is a pharmaceutical company that focuses on developing therapeutic solutions for various gastrointestinal (GI) and liver diseases. Their products aim to address unmet medical needs and improve the quality of life for patients suffering from these conditions.
- Albireo was founded in 2008 with a mission to develop and commercialize novel treatments for GI and liver diseases.
- In 2016, Albireo completed its initial public offering (IPO) and became a publicly traded company on the NASDAQ.
- The company has since continued to grow and expand its product portfolio through research and development.
- Albireo has received regulatory approvals and launched their products in several markets.
- They have also formed strategic partnerships and collaborations with other organizations to further advance their research and development efforts.
Salix Pharmaceuticals is a specialty pharmaceutical company that focuses on developing and marketing therapies for gastrointestinal disorders. They offer a range of products targeting different GI conditions.
Allergan is a global pharmaceutical company that develops and markets a wide array of products, including treatments for gastrointestinal and liver diseases. They have a diversified portfolio and a strong presence in the healthcare industry.
Takeda Pharmaceuticals is a multinational pharmaceutical company known for its expertise in gastroenterology and other therapeutic areas. They develop and market various products for GI and liver diseases.
Bylvay is Albireo's product for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). It is an oral medication that targets bile acid transporters.
Elobixibat is a product developed by Albireo for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It enhances intestinal fluid secretion and motility.
A4250 is an investigational product being developed by Albireo for the treatment of various pediatric cholestatic liver diseases. It aims to reduce bile acid levels and improve liver function.
Bylvay is approved for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). PFIC is a rare genetic disorder that affects the liver and bile ducts.
Elobixibat enhances intestinal fluid secretion and motility, which helps relieve symptoms of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).
A4250 is still under investigation and is not yet approved for use. It is being developed as a potential treatment for pediatric cholestatic liver diseases.
You can purchase Albireo's products through authorized healthcare providers and pharmacies. Please consult with your healthcare professional for more information.
Yes, Albireo is actively involved in research and development for potential therapies addressing gastrointestinal and liver diseases beyond the current portfolio. Stay updated with Albireo's official communication for any new developments.
